Arlinda Lee
Stock Analyst at Canaccord Genuity
(2.23)
# 2,612
Out of 4,836 analysts
46
Total ratings
43.48%
Success rate
7.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arlinda Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $18 → $21 | $18.10 | +16.02% | 3 | Sep 7, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $600 → $300 | $2.92 | +10,173.97% | 3 | Apr 5, 2022 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $25 → $6 | $0.70 | +763.31% | 5 | Mar 16, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $45 → $36 | $61.25 | -41.22% | 3 | Mar 7, 2022 | |
| CELC Celcuity | Initiates: Buy | $50 | $10.71 | +366.85% | 1 | Oct 8, 2021 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $151 → $160 | $38.68 | +313.65% | 3 | Aug 16, 2021 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $36 → $40 | $8.63 | +363.50% | 3 | Jul 15, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $92 → $105 | $36.19 | +190.14% | 12 | Oct 29, 2020 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $23 → $27 | $53.30 | -49.34% | 3 | May 19, 2020 | |
| BPMC Blueprint Medicines | Maintains: Buy | $115 → $100 | $101.24 | -1.22% | 5 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.11 | +2,269.67% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $270 | $5.13 | +5,168.29% | 3 | Nov 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $160 | $1.26 | +12,598.41% | 1 | Mar 29, 2018 |
Delcath Systems
Sep 7, 2023
Maintains: Buy
Price Target: $18 → $21
Current: $18.10
Upside: +16.02%
X4 Pharmaceuticals
Apr 5, 2022
Maintains: Buy
Price Target: $600 → $300
Current: $2.92
Upside: +10,173.97%
Nektar Therapeutics
Mar 16, 2022
Maintains: Buy
Price Target: $25 → $6
Current: $0.70
Upside: +763.31%
Rhythm Pharmaceuticals
Mar 7, 2022
Maintains: Buy
Price Target: $45 → $36
Current: $61.25
Upside: -41.22%
Celcuity
Oct 8, 2021
Initiates: Buy
Price Target: $50
Current: $10.71
Upside: +366.85%
CRISPR Therapeutics AG
Aug 16, 2021
Maintains: Buy
Price Target: $151 → $160
Current: $38.68
Upside: +313.65%
Bicycle Therapeutics
Jul 15, 2021
Maintains: Buy
Price Target: $36 → $40
Current: $8.63
Upside: +363.50%
Ultragenyx Pharmaceutical
Oct 29, 2020
Maintains: Buy
Price Target: $92 → $105
Current: $36.19
Upside: +190.14%
Halozyme Therapeutics
May 19, 2020
Maintains: Buy
Price Target: $23 → $27
Current: $53.30
Upside: -49.34%
Blueprint Medicines
Apr 30, 2020
Maintains: Buy
Price Target: $115 → $100
Current: $101.24
Upside: -1.22%
Feb 24, 2020
Initiates: Buy
Price Target: $50
Current: $2.11
Upside: +2,269.67%
Nov 5, 2019
Maintains: Buy
Price Target: $225 → $270
Current: $5.13
Upside: +5,168.29%
Mar 29, 2018
Maintains: Buy
Price Target: $300 → $160
Current: $1.26
Upside: +12,598.41%